Pharmaceuticals News

Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline CST with statistical significance at 6 monthsThe most common adverse events reported...

New Phase 1 data show VNA-318's mechanism of action translates from preclinical models into human biology; clear pharmacodynamic effect on the human brain

COPENHAGEN, Denmark, July 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on June 2, 2026, has now been completed, reaching an...

KØBENHAVN, Danmark, 13. juli 2026 – Bavarian Nordic A/S (OMX: BAVA) meddeler, at aktietilbagekøbsprogrammet, der blev offentliggjort og iværksat den 2. juni 2026, nu er afsluttet, da aktier til et...

National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer’s Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. Resulting...

MELBOURNE, Australia, July 13, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s novel drug SCENESSE® (afamelanotide) has been granted a Notice of Compliance (NOC) by Health Canada for the prevention of...

Pratteln, Switzerland, July 13, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending the...

Pratteln, Schweiz, 13. Juli 2026 – Santhera Pharmaceuticals (SIX: SANN) gibt heute die Erweiterung seiner exklusiven Vertriebsvereinbarung mit Biomedica für AGAMREE® (Vamorolon) bekannt. Die...

TOKYO and CAMBRIDGE, Mass., July 12, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer’s Association International...

The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1EVX-V1 is a next-generation, multi-component...